1. Home
  2. HOFT vs MDXH Comparison

HOFT vs MDXH Comparison

Compare HOFT & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hooker Furnishings Corporation

HOFT

Hooker Furnishings Corporation

HOLD

Current Price

$13.06

Market Cap

144.6M

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$2.25

Market Cap

149.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOFT
MDXH
Founded
1924
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Home Furnishings
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
144.6M
149.0M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
HOFT
MDXH
Price
$13.06
$2.25
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
26.7K
162.7K
Earning Date
04-16-2026
05-13-2026
Dividend Yield
3.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$397,465,000.00
N/A
Revenue This Year
N/A
$30.78
Revenue Next Year
$2.61
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.34
$1.36
52 Week High
$15.99
$5.33

Technical Indicators

Market Signals
Indicator
HOFT
MDXH
Relative Strength Index (RSI) 56.19 18.14
Support Level $9.22 $1.90
Resistance Level $13.47 $2.30
Average True Range (ATR) 0.71 0.21
MACD 0.17 -0.10
Stochastic Oscillator 88.45 1.13

Price Performance

Historical Comparison
HOFT
MDXH

About HOFT Hooker Furnishings Corporation

Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: